Muci specific IGE to modify myeloid derived cells of the tumor microenvironment


We have used antibody (MAb) specific to hypoglycosylated tumor associated MUC1 as a strategy to induce tumor specific immunity. Xenotypic IgG1 has been previously shown to induce T cell immunity targeting MUC1 in patients. We now describe MUC1 specific IgE to reprogram myeloid cells in the tumor microenvironment and modulate tumor specific immunity. To test… (More)